Impact Factor
4.83
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
34.78
8,256 total citations
h5-index
151
h5 depth signal
Cited share
94.1%
240 of 255
Total citations
8,256
Citation footprint
Metric signal
41.17
External metric anchor
Self-citation
0.8%
69 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
925
United States
526
Italy
122
France
114
Germany
112
Citing Fields of Research
Immunology
538
Hematology
422
Oncology
320
Lymphomas
263
Cancer & Development
201
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,210
Articles tracked across the journal lifetime
Indexed publication set
255
240 cited publications
Last 12 months
108
9.0 publications/month
Open access share
100.0%
108 OA publications in the last year
Leading citing country
China
925 citing publications
Leading citing field
Immunology
538 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1, 2008-
v1, 2008-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Hematology
Lymphomas
Oncology
Immunotherapy
Issuing & Sponsoring Bodies
Contributor
BioMed Central Ltd
Broad Categories
Hematology
Neoplasms
Immunology
Lymphomas
Immunotherapy
Cancer, Autophagy & Apoptosis
MeSH Descriptors
Hematology
Medical Oncology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1186/s13045-026-01855-x
Open DOI
CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives
Over recent years, chimeric antigen receptor T-cell (CAR-T) therapy has markedly improved outcomes for patients with relapsed or refractory hematological malignancies. Nevertheless, a substantial proportion of patients still experience r...
02
DOI 10.1186/s13045-026-01857-9
Open DOI
The advances and challenges of mRNA-LNP application in fields of hematology and oncology therapeutics
The rapidly global deployment of COVID-19 mRNA-LNP vaccines established the clinical feasibility of combining RNA medicine with LNP delivery systems, trans
03
DOI 10.1186/s13045-026-01851-1
Open DOI
AXL-directed antibody–drug conjugate therapy in soft-tissue sarcoma
AXL is a membrane-accessible receptor tyrosine kinase and a potential antibody–drug conjugate (ADC) target, but its therapeutic relevance in soft-tis
04
DOI 10.1186/s13045-026-01858-8
Open DOI
Niches in cancer: from primary tumors to metastatic disease
Cancer progression does not occur in isolation: malignant-cell states and fates are shaped by specialized microenvironments, or cancer niches. Within primary tumors, vascular, stromal, immune and neural interactions create local hypoxic,...
05
DOI 10.1186/s13045-026-01854-y
Open DOI
Novel antibody-based regimens for large B-cell lymphoma: latest updates from the 2026 ASCO Annual Meeting
Large B-cell lymphoma (LBCL) encompasses a biologically and clinically heterogeneous group of aggressive B-cell lymphomas, and outcomes remain poor in high
06
DOI 10.1186/s13045-026-01852-0
Open DOI
Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting
07
DOI 10.1186/s13045-026-01849-9
Open DOI
Current and future therapies for acute myeloblastic leukemia
08
DOI 10.1186/s13045-026-01850-2
Open DOI
T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis
Background: Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myeloma. Indirect comparisons in heavily pretreated patients have favored cell therapy, but whether t...
09
DOI 10.1186/s13045-026-01848-w
Open DOI
Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario
Tagraxofusp (TAG), a CD123-directed protein-drug conjugate, is approved in front-line and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). Multicenter real-world outcomes and the contribution of up-front consolid...
10
Bibliographical & Catalog Notes
Title from caption (publisher's Web site, viewed Apr. 3, 2009).
Latest issue consulted: 2 (Apr. 2009) (viewed Apr. 3, 2009).
Free open access electronic journal published by BioMed Central.
"As an online journal, Journal of Hematology & Oncology does not have issue numbers. Each volume corresponds to a calendar year"-- publisher's web site.
"Articles in Journal of Hematology & Oncology should be cited in the same way as articles in a traditional journal. However, because articles in this journal are not printed, they do not have page numbers. Instead, they have a unique article number. The following citation: J Hematol Oncol 2004, 2:1 refers to article 1 from volume 2 of the journal" -- publisher's web site.
Access restricted to subscribers.
Mode of access: World Wide Web.